The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2022

Filed:

Aug. 21, 2019
Applicant:

Ossianix, Inc., Philadelphia, PA (US);

Inventors:

Julien Häsler, Hoogstraten, BE;

Julia Lynn Rutkowski, Bryn Mawr, PA (US);

Assignee:

Ossianix, Inc., Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); G01N 33/68 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2875 (2013.01); A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); C07K 16/241 (2013.01); G01N 33/6872 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/22 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator ('BAFF'), thereby antagonizing BAFF receptor ('BAFF-R') signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.


Find Patent Forward Citations

Loading…